Answers are grounded in this paper and cite their sources.
Non-small cell lung cancer (NSCLC) remains a major global health burden, particularly among non-smoking Asian populations, in whom activating EGFR mutations are the predominant oncogenic drivers. The emergence of multiple resistance mutations like the T790M, C797S, and especially the clinically intractable L858R/T790M/C797S triple mutant, has rendered all existing tyrosine kinase inhibitors (TKIs) ineffective. Despite substantial advances across three generations of EGFR-TKIs, the therapeutic options available for resistant mutations remain limited. Currently no approved agent is capable of selectively and effectively targeting the triple mutant EGFR. This unmet clinical need highlights the urgency for continued drug discovery efforts aimed at overcoming resistance mediated by the C797S mutation. This need has driven intensive efforts toward developing inhibitors capable of overcoming C797S-mediated resistance. Among the scaffolds explored, pyrimidine has emerged as particularly tractable, offering favorable ligand efficiency, synthetic accessibility and multiple substitution vectors that project into the T790M-remodeled hydrophobic pocket and the region vacated by Cys797, while engaging the conserved Met793 of the hinge region. This review presents, an overview of the key structural features of the EGFR's ATP-binding site is provided to facilitate a deeper understanding of the rational design of future EGFR inhibitors.
No takes yet. Share an insight, caveat, or question.
Megha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: